RedHill Biopharma Acquires Global Rights to Rebyota and U.S. Clenpiq from Ferring
AI-generated from multiple sources. Verify before acting on this reporting.
NEW YORK — RedHill Biopharma Ltd. (NASDAQ: RDHL) announced on Wednesday that it has secured exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq in a strategic agreement with Ferring Pharmaceuticals. The deal, finalized on September 10, 2026, marks a significant expansion of RedHill's portfolio in the gastrointestinal sector, positioning the company to address both specialized treatment needs and routine medical procedures.
Under the terms of the agreement, RedHill will assume full commercial responsibility for Rebyota, a fecal microbiota product indicated for the prevention of recurrent Clostridioides difficile infection in adults. Additionally, the company will lead U.S. sales efforts for Clenpiq, an oral bowel preparation solution used prior to colonoscopy procedures. The acquisition allows RedHill to broaden its gastrointestinal coverage without requiring significant upfront cash payments, a structure designed to preserve capital while accelerating market entry.
Ferring Pharmaceuticals, a global biopharmaceutical company focused on reproductive health, urology, and gastroenterology, will continue to support the products during the transition period. The partnership leverages Ferring's established manufacturing capabilities alongside RedHill's commercial infrastructure in the United States. Industry analysts view the move as an effort by RedHill to diversify its revenue streams beyond its existing oncology and infectious disease offerings.
The transaction was structured to minimize immediate financial strain on RedHill, relying instead on milestone payments and potential royalties tied to future sales performance. This approach aligns with RedHill's broader strategy of acquiring late-stage assets that can be rapidly integrated into its sales force. By securing global rights to Rebyota, RedHill gains access to international markets where the drug is already approved or under review, while the U.S. rights to Clenpiq provide a foothold in the high-volume bowel preparation market.
Both companies stated that the deal reflects a shared commitment to improving patient outcomes in gastrointestinal health. Rebyota represents a shift toward microbiome-based therapies for recurrent infections, while Clenpiq addresses a critical need in colorectal cancer screening preparation. The integration of these two distinct therapeutic areas is expected to enhance RedHill's presence among gastroenterologists and hospital systems.
Details regarding the specific financial terms of the deal, including potential milestone payments and royalty percentages, were not disclosed at the time of the announcement. Regulators in various jurisdictions have not yet commented on the implications of the transfer of commercial rights for Rebyota outside the United States. As RedHill prepares to launch its new commercial initiatives, questions remain regarding the timeline for full market rollout and how the company plans to manage the transition of existing customer relationships from Ferring.
The agreement is expected to close subject to customary regulatory approvals and internal corporate processes. RedHill's stock price remained stable following the announcement as investors assessed the long-term potential of the expanded portfolio. The company has indicated that it will provide further updates on commercialization strategies in the coming quarter.